pre-IPO PHARMA

COMPANY OVERVIEW

NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific.


LOCATION

  • Wilmington, DE, USA
  • Radnor, PA, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders

  • WEBSITE

    http://www.neurorxpharma.com/index.html


    CAREER WEBSITE

    http://www.neurorxpharma.com/careers.html


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 25, 2021

    NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)


    Apr 28, 2021

    NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia


    Apr 19, 2021

    NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development


    Apr 6, 2021

    NeuroRx Announces Zyesami (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir


    Mar 29, 2021

    NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19


    For More Press Releases


    Google Analytics Alternative